Vuong Trieu bought $994 of OTLC
CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc.. 198,737 shares at an average of $0.01, traded Jul 8, 2025, filed Jul 10, 2025.
Score components
- +25RoleCEO
- 0Trade size$994 at market
- -5Relative to holdingsUnder 1% of holdings (0.2%)
- +4Price context29% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m 0.0%, 3m +80.0%, 6m +80.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001641172-25-018620, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 10, 2025 | POpen-market purchase Common Stock | +104,000 | $0.01 | $520 | 93,293,560 | Jul 10, 2025 |
| Jul 9, 2025 | POpen-market purchase Common Stock | +1 | $0.01 | $0 | 93,293,561 | Jul 10, 2025 |
| Jul 8, 2025 | POpen-market purchase Common Stock | +94,736 | $0.01 | $474 | 93,388,297 | Jul 10, 2025 |
Related signals
Other insiders at Oncotelic Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Oncotelic Therapeutics, Inc. | Vuong Trieu CHAIRMAN AND CEO | $10k 240,000 shares | +0% | |
| 41Moderate | Oncotelic Therapeutics, Inc. | Vuong Trieu CHAIRMAN AND CEO | $11k 255,000 shares | +0% | |
| 41Moderate | Oncotelic Therapeutics, Inc. | Amit B. Shah CFO | $1,000 20,000 shares | +6% | |
| 36Weak | Oncotelic Therapeutics, Inc. | Vuong Trieu CHAIRMAN AND CEO | $15k 335,759 shares | +0% | |
| 20Weak | OTLCbuy Oncotelic Therapeutics, Inc. | Vuong Trieu CHAIRMAN AND CEO | $8,627 298,499 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.